Latest news
Karyopharm’s selinexor misses primary endpoint in Phase 3 endometrial cancer trial - The Clinical Trial VanguardThe Clinical Trial Vanguard · Sat, 01 Aug 2026 06:33:05 GMTNovo Nordisk Sheds $50 Billion in Market Value After ZEUS Heart Drug Trial Misses Primary Goal - finance.biggo.comfinance.biggo.com · Fri, 31 Jul 2026 18:26:00 GMTSelinexor Phase 3 Trial Misses Primary Endpoint in Endometrial Cancer - The Clinical Trial VanguardThe Clinical Trial Vanguard · Fri, 31 Jul 2026 07:37:59 GMTSelinexor Misses Primary Endpoint in Endometrial Cancer Trial - MPR - Medical Professionals ReferenceMedical Professionals Reference · Fri, 31 Jul 2026 04:00:00 GMTAstraZeneca’s HSCT-TMA drug misses main endpoint - EMJEMJ · Mon, 27 Jul 2026 14:52:19 GMTAstraZeneca's rare disease drug misses main goal in late-stage trial - ReutersReuters · Mon, 27 Jul 2026 07:00:00 GMTPhase 3 Ravulizumab Trial Misses Primary End Point in Transplant-Associated Thrombotic Microangiopathy - Pharmacy TimesPharmacy Times · Mon, 27 Jul 2026 07:00:00 GMT